Download the free e-book on peptides, hormones and pharmaceuticals for longevity, health and performance here: get the e-book
There is a compound in the catalogue that represents one of the most genuinely novel mechanisms in the entire optimization space. Not novel in the sense of being untested or speculative, but novel in the sense that it works through a pathway that no other compound covered in this publication activates, targeting a biological system that until recently was not considered a practical pharmacological target at all.
That compound is SLU-PP-332. One important clarification before going further: despite appearing in peptide-focused catalogues including this one, SLU-PP-332 is not a peptide. It is a synthetic small molecule, a hydrazide derivative developed at Saint Louis University, where the SLU prefix in its name originates. Its inclusion here reflects its relevance to the optimization context rather than its classification as a peptide compound.
Understanding what SLU-PP-332 does requires understanding a class of proteins called estrogen-related receptors, what they regulate, and why activating them produces effects that researchers have described as recapitulating the metabolic benefits of endurance exercise at the molecular level.
The estrogen-related receptor family
Estrogen-related receptors, abbreviated ERRs, are a family of nuclear receptor proteins that regulate gene expression in response to cellular metabolic signals. Despite their name they are not activated by estrogen and are not directly involved in estrogen signaling. They were named for their structural similarity to estrogen receptors when they were first identified, but their function is entirely distinct.
There are three members of the family: ERR alpha, ERR beta, and ERR gamma. SLU-PP-332 is a pan-agonist, meaning it activates all three, with the highest potency at ERR alpha.
ERR alpha and ERR gamma function as master regulators of mitochondrial biogenesis and oxidative metabolism. They control the expression of genes involved in fatty acid oxidation, the citric acid cycle, oxidative phosphorylation, and mitochondrial function broadly. When these receptors are active, the cell upregulates the entire machinery of aerobic energy production, producing more mitochondria, more efficient fat burning, and greater oxidative metabolic capacity.
This is precisely the set of adaptations that endurance exercise produces. When you run, cycle, or perform sustained aerobic activity, the metabolic stress of that activity activates a cascade of signaling that ultimately drives ERR activity, which drives the mitochondrial biogenesis and metabolic adaptation that makes you fitter over time. SLU-PP-332 activates these receptors directly, bypassing the exercise stimulus and producing the downstream molecular adaptations through pharmacological activation of the same transcriptional pathway.
The research: what it shows and what it does not
The foundational work on SLU-PP-332 comes from the Burris laboratory at Saint Louis University, led by Thomas P. Burris, Ph.D. The pivotal publication, Billon et al. in Nature Metabolism in 2023, is what generated the widespread attention this compound has received and the exercise in a pill framing that followed.
In that study, conducted in male mice over four weeks of treatment, SLU-PP-332 produced a 45 to 70 percent increase in treadmill endurance, a 13 percent reduction in total fat mass in a diet-induced obesity model, improved glucose tolerance, and a muscle transcriptional signature that reproduced approximately 80 percent of the genes induced by a four-week endurance training protocol. These are striking results that justify the scientific interest the compound has generated.
What must be stated clearly is that as of 2026, there is no human data for SLU-PP-332. No human clinical trials have been conducted. No Investigational New Drug application has been filed. No human pharmacokinetic or safety data has been published. Every efficacy and safety figure in the literature comes from mouse models and in-vitro studies. Vendor safety data sheets list no data available for every toxicology endpoint including acute toxicity, mutagenicity, carcinogenicity, and reproductive toxicity.
This does not mean the preclinical results are irrelevant. The mechanism is well understood, the animal data is internally consistent and compelling, and the biological rationale for human translation is sound. It does mean that the certainty appropriate to compounds with human clinical trial data behind them is not warranted for SLU-PP-332, and that representing it with the same confidence as established compounds would be inaccurate.
The exercise mimetic concept
The term exercise mimetic describes a compound that produces some or all of the molecular adaptations that exercise produces without requiring the physical activity itself. SLU-PP-332 is not the first compound in this category. GW501516, which activates PPAR delta, was an earlier research compound that produced similar metabolic adaptations in preclinical models. It was not pursued for human use due to cancer-related findings in long-term animal studies.
SLU-PP-332 represents a more targeted approach through ERR activation and its preliminary preclinical safety profile has not shown the concerns that limited GW501516. Whether this safety profile translates to humans remains unknown in the absence of human data.
Who SLU-PP-332 is most relevant for
In the optimization context, SLU-PP-332 maps most naturally to situations where the mitochondrial and metabolic adaptations of endurance exercise are a priority.
For people with cardiovascular or metabolic limitations that restrict sustained aerobic exercise, SLU-PP-332 theoretically offers a pharmacological pathway to some of the cellular adaptations that training would otherwise produce. For people who train regularly and want to accelerate the mitochondrial adaptation component of their fitness development, it adds ERR activation alongside the exercise stimulus. For longevity-focused protocols where mitochondrial density and oxidative capacity are priorities, it addresses the biogenesis dimension in a way that complements SS-31, NAD+, and MOTS-C from a distinct angle.
SS-31 protects existing mitochondrial structure. NAD+ supports the energy substrate. MOTS-C supports mitochondrial signaling. SLU-PP-332 drives the creation of new mitochondria and the upregulation of the oxidative metabolic program. Together they address mitochondrial health from four distinct angles.
The honest positioning
SLU-PP-332 has a compelling mechanism, striking preclinical results, and a clear biological rationale for the effects it produces in animal models. It also has no human data, no registered clinical trials, and no established safety profile in humans.
For practitioners and clients who understand that distinction and are willing to engage with a compound at this stage of evidence development, SLU-PP-332 represents one of the most mechanistically interesting additions to the optimization toolkit. For those who require human clinical evidence before considering a compound, the honest answer is that evidence does not yet exist.
What it is not, under any framing, is a replacement for exercise. The adaptations that endurance training produces extend well beyond ERR activation to include cardiovascular remodeling, bone density, neurological benefits, and the metabolic and psychological benefits of physical exertion that no compound fully replicates. SLU-PP-332 activates one important part of the exercise adaptation pathway. It does not replicate the whole of what exercise does.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making any changes to your health regimen. For more information visit www.peakformrx.health